Recent Updates
Recently added Catalysts
SGHT Positive Sentiment

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Key Takeaway: Sight Sciences, Inc. announces its upcoming presentation at the 24th Annual Needham Healthcare Conference on April 8, 2025. The event will be held virtually, and interested viewers can access the live and archived webcast through the company's website. Sight Sciences is dedicated to developing innovative eyecare technologies aimed at transforming care for eye diseases, including its advanced surgical systems and therapies for glaucoma and dry eye disease.
Price reaction · baseline $3.07 (2025-03-24 close) · hit after-hours · clean, no other SGHT news in the window
day 0 close
-12.4%
day 1
-12.9%
day 3 · peak
-16.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sight Sciences is scheduled to present at a prominent healthcare conference.
  • The company focuses on innovative eyecare technologies that aim to improve patients' lives.
  • The presentation can be accessed online, providing wider accessibility to interested parties.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~42 mo
Low dilution risk
Lead asset
Restasis
Phase 1 · Ocular Surface Disease

Full Press Release Details

MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually.
Sight Sciences’ management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.

Frequently Asked Questions

When will Sight Sciences present at the Needham Conference?

Sight Sciences will present on April 8, 2025, at 12:45 pm PT.

Where can I access the webcast of the Sight Sciences presentation?

The webcast can be accessed in the 'Investors' section of their website.

What is the purpose of Sight Sciences?

Sight Sciences focuses on developing innovative technologies to improve eye care.

What does the OMNI® Surgical System treat?

The OMNI® Surgical System is indicated for reducing intraocular pressure in glaucoma.

What condition does the TearCare® System address?

The TearCare® System treats evaporative dry eye due to meibomian gland disease.

Last updated: Mar 25, 2025